🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A radioimmunotherapy agent based on the YS5 antibody "suppressed the growth of cell-derived & patient-derived #xenografts," say UCSF Imaging researchers & collaborators in AACR. bit.ly/3q76Ycf

Congrats Paul Klauser Lei Wang Kondapa Naidu Bobba Michael Evans! Great example of using new technologies to enhance #theranostics

.UCSF Imaging's Dr. Kondapa Naidu Bobba (Kondapa Naidu Bobba) is first author of "Evaluation of 134Ce/134La as a PET Imaging Theranostic Pair For 225Ac -Radiotherapeutics," a JNM article that discusses a robust radiolabeling methodology & more. bit.ly/3MYgaYq

Congrats Niranjan Meher on this article! Nice discussion on the intersection of PSMA theranostics and nanotechnology.

Congratulations are in order for Henry VanBrocklin, PhD, FSNMMI, FSRS, the 2023 recipient of the prestigious SNMMI Paul C. Aebersold Award for outstanding achievement in basic nuclear medicine science. ow.ly/sF3l50OWAT6 #SNMMI23 #NuclearMedicine

#SNMMI23 Abstract Highlight: New radiopharmaceutical therapy target identified for metastatic #BladderCancer. ow.ly/hpVI50OWB8v #NuclearMedicine #RPTherapy

"Henry VanBrocklin is a deserving recipient of the SNMMI Aebersold Award," says @UCSFImaging Chair Chris Hess (Christopher Hess). "He's a distinguished member of the int'l nuclear medicine & molecular imaging community & has immeasurably improved patient care." radiology.ucsf.edu/blog/ucsfs-hen…

🔬 Dr. K Naidu Bobba (Kondapa Naidu Bobba), the first author from Prof. Robert Flavell's lab (Rob Flavell ) at UCSF Imaging UC San Francisco , shares his work on "A Theranostic Duo: Cerium and Lanthanum for Enhanced Alpha Radiotherapy" in JNM

Innovative research from UCSF Imaging's Drs. Shalini Chopra, Kondapa Naidu Bobba, Youngho Seo, Rob Flavell, Michael Evans & collaborators demonstrates irreversible binding to target proteins, leading to higher radioisotope levels in tumors. doi.org/10.1021/acscen…

Congrats to Anil Bidkar SurekhaYadav MD and co-authors on the timely review on Actinium-225 targeted alpha particle therapy for prostate cancer! Lots of promise for this treatment modality. thno.org/v14p2969.htm #Theranostics

We're excited to see everyone at #SNMMI24! UCSF Imaging's #postdoc Anil Bidkar (Anil Bidkar) will be presenting about using targeted alpha particle therapy to treat metastatic prostate cancer in tumor models today at 3:30 p.m. SNMMI

Excited that our new paper is out! Led by Deblin Jana Brown Engineering The Desai Lab @ UCSF in collaboration with Rob Flavell UCSF Imaging , we show enhanced prostate specific membrane antigen targeting by DNA scaffolded nanoparticle ligand presentation ACS Nano pubs.acs.org/doi/full/10.10…

New in #Theranostics from UCSF Imaging's Drs. Anil Bidkar (Anil Bidkar), Luann Zerefa, Surekha Yadav (SurekhaYadav MD), Henry VanBrocklin & Robert Flavell (Rob Flavell): "Actinium-225 targeted alpha particle therapy for prostate cancer." thno.org/v14p2969.htm

At the #2024PSMAConference, Rob Flavell discussed the promise of antibody-based radiopharmaceuticals for prostate cancer, highlighting their high specificity and addressing challenges like long half-lives. #WatchNow on UroToday > bit.ly/4aRdsha PSMA & Beyond Conference

Exciting news from Flavell Lab(Rob Flavell)! Our latest study on CD46-targeted Actinium-225 alpha particle therapy for disseminated prostate cancer is now online in Clinical Cancer Research. Read it Clinical Cancer Research: bit.ly/3CYw4Rq #ProstateCancer #Ac225 #CD46 #Theranostics

Effective treatment of disseminated #ProstateCancer using CD46-targeted 225Ac therapy. #AuthorCommentary New hope for PSMA-negative #ProstateCancer: CD46-targeted 225Ac alpha therapy shows strong preclinical efficacy in disseminated mCRPC models. Early treatment = better

Congrats to Anil Bidkar on leading this work integrating alpha particle microdosimetry with therapeutic efficacy, and demonstrating the potential of CD46 RPT in the context of disseminated preclinical models.

Effective treatment of disseminated #ProstateCancer using CD46-targeted 225Ac therapy. #AuthorCommentary New hope for PSMA-negative #ProstateCancer: CD46-targeted 225Ac alpha therapy shows strong preclinical efficacy in disseminated mCRPC models. Early treatment = better

Had fun collaborating with Ravi Patel (Ravi Patel) & Steve Adler (NIH Intramural) on this commentary highlighting Rob Flavell's (Rob Flavell) & Anil Bidkar's recent publication showing superior efficacy of alpha #radiopharmaceuticals therapy in micro v macromets 👇

A combination of a CD46-targeted antibody-drug conjugate and a radioimmunotherapy agent for the treatment of #ProstateCancer. Presentation by Anil Bidkar UC San Francisco. #SNMMI25 written coverage by Rashid K. Sayyid USC > bit.ly/4n9aPyJ SNMMI #SNMMI2025